AlveoliX

AlveoliX is a pioneering biotechnology research company dedicated to transforming drug development through advanced in-vitro models. Inspired by nature, AlveoliX develops organs-on-chips that accurately replicate the in-vivo environment, offering unprecedented predictive capabilities for drug responses in humans. This innovative approach significantly reduces the need for animal testing and accelerates the development of effective therapies.

Located at Freiburgstrasse 3, Bern, 3010, CH, AlveoliX is committed to improving preclinical decision-making and reducing drug development costs with its unique organ-on-chip technologies. By providing in-vitro solutions that closely mimic human physiology, AlveoliX empowers researchers to make more informed decisions early in the drug development process.

AlveoliX is at the forefront of innovation in respiratory disease research and drug discovery. The company’s commitment to safety, efficacy, and technological advancement positions it as a key partner for organizations seeking to revolutionize their preclinical strategies. We invite the manager of AlveoliX to create a customized and exclusive company showcase and product listing on our platform to further amplify their impact.